Research & Education

Illumina Inc (ILMN) Fair Value: Overvalued at Current Prices

2026-06-25 · fairvalue-calculator.com

By Dr. Peter Klein, BA · Founder

Illumina Inc Fair Value Analysis: Why ILMN Appears Overvalued

Illumina Inc (ILMN) is the leading provider of next-generation sequencing (NGS) technology used in genetic research, clinical diagnostics, and drug development. At a recent price of $164.93, our fair value model places the stock at $95.51, implying a significant -42.1% downside and classifying it as overvalued. The company earns a respectable Quality Score of 78/100, reflecting strong fundamentals in a high-tech healthcare niche, yet valuation metrics suggest the market has priced in overly optimistic growth assumptions.

What Illumina Does and Its Market Position

Founded in 1998 and headquartered in San Diego, Illumina develops, manufactures, and markets integrated systems for analyzing genetic variation and biological function. Its flagship platforms, including the NovaSeq X series, power the majority of global DNA sequencing. The business model centers on high-margin consumables and recurring revenue from reagents, flow cells, and software services, serving academic institutions, pharmaceutical companies, and clinical labs worldwide. Clinical applications, such as oncology testing and rare disease diagnostics, represent a growing portion of sales as genomic medicine expands.

Recent Performance and 2026 Outlook

In Q1 fiscal 2026, Illumina delivered revenue of $1.09 billion, a 4.8% increase year-over-year with 3.5% organic growth outside China. Non-GAAP operating margin reached 21.9%, and diluted EPS came in at $1.15, beating analyst expectations. Management raised full-year 2026 revenue guidance modestly to $4.52–$4.62 billion (4–6% reported growth) and non-GAAP EPS to $5.15–$5.30, while authorizing an additional $1.5 billion for share repurchases. These results underscore steady execution in core markets but highlight that explosive growth from prior years has moderated.

Key Valuation Drivers Behind the Fair Value Estimate

Our proprietary fair value calculation incorporates discounted cash flow projections anchored to conservative revenue growth, margin expansion potential, and capital allocation. Primary drivers include:

Revenue trajectory: Clinical and international consumables growth supports mid-single-digit top-line expansion, tempered by competition and reimbursement challenges.
Margin profile: High gross margins near 70% provide a buffer, but operating leverage is limited by R&D intensity and sales investments.
Capital returns and balance sheet: Share buybacks offer support, yet the absence of dividends and elevated share count historically weigh on per-share value creation.
Quality Score inputs: The 78/100 rating reflects solid profitability and market leadership but factors in execution risks in a rapidly evolving technology landscape.

At current levels, the implied multiple on forward earnings exceeds what our model deems sustainable given the growth outlook.

💡 Theory is good — numbers are better. Get the fair value of any stock worldwide in seconds. Try it free →

Want to run your own scenarios? Check the free Fair Value Calculator to evaluate Illumina Inc alongside 10,000+ other stocks using 21 valuation models.

Main Risks to Consider

Several headwinds could pressure future results and justify the discounted fair value:

Intense competition from emerging long-read sequencing technologies and lower-cost alternatives.
Regulatory and reimbursement hurdles for clinical genomic tests in key markets like the U.S. and Europe.
Geopolitical exposure, particularly in China, where past restrictions impacted growth.
Technological obsolescence risk as sequencing speeds and costs continue to improve industry-wide.
Macroeconomic sensitivity affecting research budgets at academic and biotech customers.

While the Quality Score of 78/100 indicates resilience, these factors cap upside potential in our base case.

Balanced Verdict on Illumina Stock

Illumina remains a cornerstone of the genomics revolution with durable competitive advantages in sequencing infrastructure. However, after factoring in modest 2026 guidance, competitive dynamics, and normalized growth expectations, our model concludes the shares trade at a meaningful premium to intrinsic value. Investors focused on margin of safety may find better opportunities elsewhere, while those bullish on clinical adoption could monitor upcoming quarterly updates for positive surprises. This analysis is educational and not financial advice—always conduct your own due diligence.

Explore more stocks and valuation models on our fair value calculator homepage.

Frequently Asked Questions

What is Illumina Inc's current fair value according to the model?

Our fair value estimate for Illumina Inc (ILMN) is $95.51 per share, compared to the recent trading price of $164.93, indicating the stock is overvalued by approximately 42%.

Why does the fair value calculator consider Illumina overvalued?

Key drivers include modest revenue growth guidance of 4-6% for 2026, elevated valuation multiples relative to earnings potential, ongoing competitive and regulatory risks in the genomics sector, despite a solid Quality Score of 78/100.

What recent earnings did Illumina report for Q1 2026?

Illumina reported Q1 2026 revenue of $1.09 billion (up 4.8% YoY) and non-GAAP EPS of $1.15, beating estimates, with full-year revenue guidance raised slightly to $4.52-$4.62 billion.

Sources

Context gathered via live web search while writing this article:

Check the fair value of any stock worldwide
26 valuation models · 12,000+ stocks · evidence-based
Start free →

Educational research only · Not financial advice · No buy/sell recommendations · Past performance is not a guarantee of future results.